vinflunine,docetaxel,erdafitinib,pembrolizumab
pierre fabre,merck,janssen
['erdafitinib', 'thor study', 'muc ,(-much)']
outstanding presentation by of thor study : erdafitinib vs chemo in muc with fgfr alterations previously treated. os benefit (12 vs 8 months, hr 0.64, p=0.005). molecular testing at metastatic stage in all patients is essential +++ #asco2023
Medical oncologist, Urologic Oncology @HopitalPompidou @APHP Paris (France)